Juvenile Idiopathic Arthritis

Trials

200 participants · First posted Jun 8, 2026

Completed

NCT00783510

Juvenile Idiopathic Arthritis (JIA) Registry

849 participants · First posted Oct 31, 2008

Completed

NCT04664231

Spine Deformities in Juvenile Idiopathic Arthritis

257 participants · First posted Dec 11, 2020

Drugs

View all 158 →

Small Molecule

Approved

Naproxen(Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo)

Manufacturer: Roche palo alto llc, Roxane laboratories inc +28 more

Conditions: Acute Gouty Arthritis, Acute Migraine +24 more

C₁₄H₁₄O₃

Biotech

Approved

Tocilizumab(Actemra, RoActemra, Tyenne, Tofidence, Avtozma)

Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy +9 more

Rx

Biotech

Approved

Canakinumab(Ilaris)

Manufacturer: Novartis

Conditions: Adult Onset Still's Disease, Cryopyrin-associated Periodic Syndromes (CAPS) +7 more

Organizations

View all 21 →

CARE Arthritis Ltd

Canada

Arthritis Innovation Corporation

Canada

The Stone Research Foundation For Sports Medicine and Arthritis

United States

News

View all 1333 →

last year

FDA Expands Jylamvo Approval to Include Polyarticular Juvenile Idiopathic Arthritis and ALL

last year

FDA Grants Rare Pediatric Disease Designation to 101-PGC-005 for Systemic Juvenile Idiopathic Arthritis

last year

Trials

Sarcopenia and Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis (JIA) Registry

Spine Deformities in Juvenile Idiopathic Arthritis

Drugs

Naproxen(Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo)

Tocilizumab(Actemra, RoActemra, Tyenne, Tofidence, Avtozma)

Canakinumab(Ilaris)

Organizations

CARE Arthritis Ltd

Arthritis Innovation Corporation

The Stone Research Foundation For Sports Medicine and Arthritis

News

FDA Expands Jylamvo Approval to Include Polyarticular Juvenile Idiopathic Arthritis and ALL

FDA Grants Rare Pediatric Disease Designation to 101-PGC-005 for Systemic Juvenile Idiopathic Arthritis

FDA Expands Methotrexate Approval for Pediatric ALL and Juvenile Idiopathic Arthritis